Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve,
escape coronavirus disease 2019 therapeutics and vaccines, and jeopardize public health …

SARS-CoV-2 Omicron variant has presented significant challenges to current antibodies
and vaccines. Herein, we systematically compared the efficacy of 50 human monoclonal …

The highly mutated and transmissible Omicron (BA. 1) and its more contagious lineage BA.
2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) neutralizing antibodies
are shown to be effective therapeutics for providing coronavirus disease 2019 (COVID‐19) …

Summary SARS-CoV-2 Omicron BA. 2.75 subvariant has evolved to a series of progeny
variants carrying several additional mutations in the receptor-binding domain (RBD). Here …

Coronaviruses have been the causative agent of three epidemics and pandemics in the past
two decades, including the ongoing COVID-19 pandemic. A broadly-neutralizing …

ABSTRACT Coronavirus disease 2019 (COVID-19) is an evolving global public health crisis
in need of therapeutic options. Passive immunization of monoclonal antibodies (mAbs) …

The emergence of SARS-CoV-2 variants of concern (VOCs) requires the development of
next-generation biologics with high neutralization breadth. Here, we characterized a human …

One major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of
costly cocktails to reduce emergence of antibody resistance. Here we engineer two …

Emerging SARS-CoV-2 variants have accrued mutations within the spike protein rendering
most therapeutic monoclonal antibodies against COVID-19 ineffective. Hence there is an …